{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T21:25:42Z","timestamp":1778361942330,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T00:00:00Z","timestamp":1499904000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s11307-017-1101-y","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T15:22:01Z","timestamp":1499959321000},"page":"933-943","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["[68Ga]PSMA-HBED-CC Uptake in Osteolytic, Osteoblastic, and Bone Marrow Metastases of Prostate Cancer Patients"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4754-4123","authenticated-orcid":false,"given":"Jan-Carlo","family":"Janssen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Woythal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Mei\u00dfner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winfried","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"Diederichs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus R.","family":"Makowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,13]]},"reference":[{"key":"1101_CR1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87\u2013108","journal-title":"CA Cancer J Clin"},{"key":"1101_CR2","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","volume":"31","author":"L Bubendorf","year":"2000","unstructured":"Bubendorf L, Schopfer A, Wagner U et al (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31:578\u2013583","journal-title":"Hum Pathol"},{"key":"1101_CR3","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1002\/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO;2-Q","volume":"88","author":"BI Carlin","year":"2000","unstructured":"Carlin BI, Andriole GL (2000) The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 88:2989\u20132994","journal-title":"Cancer"},{"key":"1101_CR4","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/1097-0142(19830301)51:5<918::AID-CNCR2820510526>3.0.CO;2-J","volume":"51","author":"SA Charhon","year":"1983","unstructured":"Charhon SA, Chapuy MC, Delvin EE et al (1983) Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer 51:918\u2013924","journal-title":"Cancer"},{"key":"1101_CR5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4137\/CGM.S12769","volume":"6","author":"S Dushyanthen","year":"2013","unstructured":"Dushyanthen S, Cossigny DA, Quan GM (2013) The osteoblastic and osteoclastic interactions in spinal metastases secondary to prostate cancer. Cancer Growth Metastasis 6:61\u201380","journal-title":"Cancer Growth Metastasis"},{"key":"1101_CR6","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/cncr.24896","volume":"116","author":"T Ibrahim","year":"2010","unstructured":"Ibrahim T, Flamini E, Mercatali L et al (2010) Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer 116:1406\u20131418","journal-title":"Cancer"},{"key":"1101_CR7","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584\u2013593","journal-title":"Nat Rev Cancer"},{"key":"1101_CR8","first-page":"144","volume":"4","author":"GD Roodman","year":"2004","unstructured":"Roodman GD (2004) Mechanisms of bone metastasis. Discov Med 4:144\u2013148","journal-title":"Discov Med"},{"key":"1101_CR9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1022627421000","volume":"20","author":"MP Roudier","year":"2003","unstructured":"Roudier MP, Vesselle H, True LD et al (2003) Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 20:171\u2013180","journal-title":"Clin Exp Metastasis"},{"key":"1101_CR10","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1172\/JCI31791","volume":"117","author":"RS Taichman","year":"2007","unstructured":"Taichman RS, Loberg RD, Mehra R, Pienta KJ (2007) The evolving biology and treatment of prostate cancer. J Clin Invest 117:2351\u20132361","journal-title":"J Clin Invest"},{"key":"1101_CR11","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1002\/ijc.26024","volume":"128","author":"JK Jin","year":"2011","unstructured":"Jin JK, Dayyani F, Gallick GE (2011) Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer 128:2545\u20132561","journal-title":"Int J Cancer"},{"key":"1101_CR12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejrad.2015.10.012","volume":"85","author":"MB Lange","year":"2016","unstructured":"Lange MB, Nielsen ML, Andersen JD et al (2016) Diagnostic accuracy of imaging methods for the diagnosis of skeletal malignancies: a retrospective analysis against a pathology-proven reference. Eur J Radiol 85:61\u201367","journal-title":"Eur J Radiol"},{"key":"1101_CR13","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.biopha.2012.06.004","volume":"66","author":"L Evangelista","year":"2012","unstructured":"Evangelista L, Panunzio A, Polverosi R et al (2012) Early bone marrow metastasis detection: the additional value of FDG-PET\/CT vs. CT imaging. Biomed Pharmacother 66:448\u2013453","journal-title":"Biomed Pharmacother"},{"key":"1101_CR14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh A, Malcher A, Eder M et al (2013) PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40:486\u2013495","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1101_CR15","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/ph7070779","volume":"7","author":"M Eder","year":"2014","unstructured":"Eder M, Neels O, Muller M et al (2014) Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel) 7:779\u2013796","journal-title":"Pharmaceuticals (Basel)"},{"key":"1101_CR16","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1021\/bc200279b","volume":"23","author":"M Eder","year":"2012","unstructured":"Eder M, Schafer M, Bauder-Wust U et al (2012) 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 23:688\u2013697","journal-title":"Bioconjug Chem"},{"key":"1101_CR17","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber M, Maurer T, Souvatzoglou M et al (2015) Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56:668\u2013674","journal-title":"J Nucl Med"},{"key":"1101_CR18","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","volume":"195","author":"T Maurer","year":"2016","unstructured":"Maurer T, Gschwend JE, Rauscher I et al (2016) Diagnostic efficacy of 68Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 195:1436\u20131443","journal-title":"J Urol"},{"key":"1101_CR19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","volume":"42","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Avtzi E, Giesel FL et al (2015) The diagnostic value of PET\/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42:197\u2013209","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1101_CR20","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s11307-016-0945-x","volume":"18","author":"V Prasad","year":"2016","unstructured":"Prasad V, Steffen IG, Diederichs G et al (2016) Biodistribution of [68Ga]PSMA-HBED-CC in patients with prostate cancer: characterization of uptake in normal organs and tumour lesions. Mol Imaging Biol 18:428\u2013436","journal-title":"Mol Imaging Biol"},{"key":"1101_CR21","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1007\/s00259-016-3435-0","volume":"43","author":"T Pyka","year":"2016","unstructured":"Pyka T, Okamoto S, Dahlbender M et al (2016) Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 43:2114\u20132121","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1101_CR22","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","volume":"17","author":"M Dietlein","year":"2015","unstructured":"Dietlein M, Kobe C, Kuhnert G et al (2015) Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol 17:575\u2013584","journal-title":"Mol Imaging Biol"},{"key":"1101_CR23","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1097\/RLU.0000000000000783","volume":"40","author":"F Ceci","year":"2015","unstructured":"Ceci F, Castellucci P, Graziani T et al (2015) 11C-choline PET\/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer. Clin Nucl Med 40:e265\u2013e270","journal-title":"Clin Nucl Med"},{"key":"1101_CR24","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.eururo.2005.12.045","volume":"49","author":"F Saad","year":"2006","unstructured":"Saad F, Clarke N, Colombel M (2006) Natural history and treatment of bone complications in prostate cancer. Eur Urol 49:429\u2013440","journal-title":"Eur Urol"},{"key":"1101_CR25","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1186\/1471-2407-13-605","volume":"13","author":"S Rafiei","year":"2013","unstructured":"Rafiei S, Komarova SV (2013) Molecular signaling pathways mediating osteoclastogenesis induced by prostate cancer cells. BMC Cancer 13:605","journal-title":"BMC Cancer"},{"key":"1101_CR26","doi-asserted-by":"crossref","first-page":"626","DOI":"10.2174\/1566524011313040012","volume":"13","author":"JL Sottnik","year":"2013","unstructured":"Sottnik JL, Keller ET (2013) Understanding and targeting osteoclastic activity in prostate cancer bone metastases. Curr Mol Med 13:626\u2013639","journal-title":"Curr Mol Med"},{"key":"1101_CR27","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1172\/JCI11685","volume":"107","author":"J Zhang","year":"2001","unstructured":"Zhang J, Dai J, Qi Y et al (2001) Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107:1235\u20131244","journal-title":"J Clin Invest"},{"key":"1101_CR28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","volume":"379","author":"MR Smith","year":"2012","unstructured":"Smith MR, Saad F, Coleman R et al (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379:39\u201346","journal-title":"Lancet"},{"key":"1101_CR29","first-page":"473","volume":"5","author":"I Fogelman","year":"1980","unstructured":"Fogelman I (1980) Skeletal uptake of diphosphonate: a review. Eur J Nucl Med 5:473\u2013476","journal-title":"Eur J Nucl Med"},{"key":"1101_CR30","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/snuc.2001.23527","volume":"31","author":"GJ Cook","year":"2001","unstructured":"Cook GJ, Fogelman I (2001) The role of nuclear medicine in monitoring treatment in skeletal malignancy. Semin Nucl Med 31:206\u2013211","journal-title":"Semin Nucl Med"},{"key":"1101_CR31","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2967\/jnumed.116.178533","volume":"58","author":"H Ahmadzadehfar","year":"2017","unstructured":"Ahmadzadehfar H, Azgomi K, Hauser S et al (2017) 68Ga-PSMA-11 PET as a gatekeeper for the treatment of metastatic prostate cancer with 223Ra: proof of concept. J Nucl Med 58:438\u2013444","journal-title":"J Nucl Med"},{"key":"1101_CR32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejrad.2005.01.016","volume":"55","author":"N Ghanem","year":"2005","unstructured":"Ghanem N, Uhl M, Brink I et al (2005) Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET\/CT for the detection of metastases of bone. Eur J Radiol 55:41\u201355","journal-title":"Eur J Radiol"},{"key":"1101_CR33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C et al (2017) German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 58:85\u201390","journal-title":"J Nucl Med"},{"key":"1101_CR34","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2967\/jnumed.114.147413","volume":"56","author":"M Benesova","year":"2015","unstructured":"Benesova M, Schafer M, Bauder-Wust U et al (2015) Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med 56:914\u2013920","journal-title":"J Nucl Med"},{"key":"1101_CR35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2967\/jnumed.116.178483","volume":"58","author":"S Okamoto","year":"2017","unstructured":"Okamoto S, Thieme A, Allmann J et al (2017) Radiation dosimetry for 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions. J Nucl Med 58:445\u2013450","journal-title":"J Nucl Med"},{"key":"1101_CR36","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s00259-016-3609-9","volume":"44","author":"L Scarpa","year":"2017","unstructured":"Scarpa L, Buxbaum S, Kendler D et al (2017) The 68Ga\/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates. Eur J Nucl Med Mol Imaging 44:788\u2013800","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1101_CR37","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.eururo.2012.02.020","volume":"62","author":"FE Lecouvet","year":"2012","unstructured":"Lecouvet FE, El Mouedden J, Collette L et al (2012) Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc-99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62:68\u201375","journal-title":"Eur Urol"},{"key":"1101_CR38","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.2214\/AJR.15.15761","volume":"206","author":"S Woo","year":"2016","unstructured":"Woo S, Kim SY, Kim SH, Cho JY (2016) Journal club: identification of bone metastasis with routine prostate MRI: a study of patients with newly diagnosed prostate cancer. AJR Am J Roentgenol 206:1156\u20131163","journal-title":"AJR Am J Roentgenol"},{"key":"1101_CR39","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/RLU.0000000000001296","volume":"41","author":"JK Blazak","year":"2016","unstructured":"Blazak JK, Thomas P (2016) Paget disease: a potential pitfall in PSMA PET for prostate cancer. Clin Nucl Med 41:699\u2013700","journal-title":"Clin Nucl Med"},{"key":"1101_CR40","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1097\/RLU.0000000000001222","volume":"41","author":"P Gykiere","year":"2016","unstructured":"Gykiere P, Goethals L, Everaert H (2016) Healing sacral fracture masquerading as metastatic bone disease on a 68Ga-PSMA PET\/CT. Clin Nucl Med 41:e346\u2013e347","journal-title":"Clin Nucl Med"},{"key":"1101_CR41","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/RLU.0000000000001631","volume":"42","author":"C Artigas","year":"2017","unstructured":"Artigas C, Otte FX, Lemort M et al (2017) Vertebral hemangioma mimicking bone metastasis in 68Ga-PSMA ligand PET\/CT. Clin Nucl Med 42:368\u2013370","journal-title":"Clin Nucl Med"},{"key":"1101_CR42","doi-asserted-by":"publisher","unstructured":"Fendler WP, Calais J, Allen-Auerbach M et al (2017) 68Ga-PSMA-11 PET\/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study. J Nucl Med. doi: 10.2967\/jnumed.117.190827","DOI":"10.2967\/jnumed.117.190827"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11307-017-1101-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-017-1101-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-017-1101-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,29]],"date-time":"2019-09-29T22:52:39Z","timestamp":1569797559000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11307-017-1101-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,13]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1101"],"URL":"https:\/\/doi.org\/10.1007\/s11307-017-1101-y","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,13]]}}}